Skip to main content

Drug Interactions between dabigatran and elbasvir / grazoprevir

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

dabigatran elbasvir

Applies to: dabigatran and elbasvir / grazoprevir

Coadministration with elbasvir may increase plasma concentrations of some P-glycoprotein (P-gp) substrates. The clinical significance of this interaction has not been established. Elbasvir is an inhibitor of P-gp in vitro, but appears to have minimal intestinal P-gp inhibition in humans. When elbasvir was coadministered with the P-gp substrate, digoxin, there was an 11% increase in digoxin systemic exposure, which was not considered clinically relevant. Nevertheless, some concern exists regarding the potential effect on other drugs that are sensitive P-gp substrates such as dabigatran, since elevated plasma levels may increase the risk of bleeding.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):

Switch to consumer interaction data

Drug and food interactions

Minor

grazoprevir food

Applies to: elbasvir / grazoprevir

Food does not appear to have clinically significant effects on the pharmacokinetics of elbasvir and grazoprevir. When a single 50 mg-100 mg dose of elbasvir-grazoprevir was administered to healthy study subjects with a high-fat meal (900 kcal; 500 kcal from fat), elbasvir peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 15% and 11%, respectively, while grazoprevir Cmax and AUC increased by 2.8- and 1.5-fold, respectively, compared to administration under fasting conditions. According to the product labeling, elbasvir-grazoprevir may be administered with or without food.

References

  1. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer